GSK-CIL103657

Study Sponsor: GSK

Study Title

A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients with Chronic Obstructive Pulmonary Disease (COPD)

Medicine or Vaccine (generic name)

cilomilast

Sponsor Identification Number

CIL103657

Trial Registry Identification Number(#'s)

NCT00103922

Medical Condition

Pulmonary Disease, Chronic Obstructive

Phase

Phase 3

Link to GSK Study Register

https://www.gsk-studyregister.com/en/trial-details/?id=CIL103657

Link to study details on ClinicalTrials.gov (if available)

http://clinicaltrials.gov/show/NCT00103922

Link to study details on EudraCT (if available)

Datasets and Documents Available for this Study

Raw dataset	Annotated case report form	Dataset specifications	Protocol with any amendments
Analysis-ready dataset	Reporting and analysis plan	Clinical study report	Ready to Share

Additional information about the data and documents available for this study

An annotated case report form is not available for this study. A blank case report form will be provided.

Date Added to this Site

November 2014